Trends in opioid use and dosing among socio-economically disadvantaged patients

Open Medicine

Volumn 5, Issue 1, 2011, Pages 13-22

  Gomes, Tara ^a   Juurlink, David N ^b   Dhalla, Irfan A ^c   Mailis Gagnon, Angngela ^d   Paterson, J Michael ^e   Mamdani, Muhammad M ^e,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANADA; CHRONIC DISEASE; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; DRUG TOXICITY; ECONOMICS; FEMALE; HEALTH CARE POLICY; HEALTH DISPARITY; HUMAN; INCOME; MALE; MIDDLE AGED; MORTALITY; PAIN; POISSON DISTRIBUTION; POVERTY; RISK; SOCIOECONOMICS; STATISTICS;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; CHRONIC DISEASE; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DRUG TOXICITY; FEMALE; HEALTH POLICY; HEALTH STATUS DISPARITIES; HUMANS; INCOME; MALE; MIDDLE AGED; MORPHINE; ONTARIO; PAIN; POISSON DISTRIBUTION; POVERTY; RISK; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 79251563771     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-130.
2. Gardner-Nix J. Principles of opioid use in chronic noncancer pain. CMAJ 2003;169(1):38-43.
3. World Health Organization. Achieving balance in national opioids control policy: Guidelines for assessment. Geneva: The Organization; 2000.
4. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112(3)372-380.
5. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174(11)1589-1594.
6. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003;28(5)1026-1048.
7. Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146(2)116-127.
8. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010 Jan 20;(1):CD006605.
9. Eriksen J, Sjøgren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125(1-2):172-179.
10. Wallace M, Moulin DE, Rauck RL, Khanna S, Tudor IC, Skowronski R, et al. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag 2009;5(2):97-105.
11. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician 2008;11(2 Suppl):S181-200.
12. Spiller H, Lorenz DJ, Bailey EJ, Dart RC. Epidemiological trends in abuse and misuse of prescription opioids. J Addict Dis 2009;28(2):130-136.
13. Boyd CJ, Teter CJ, West BT, Morales M, McCabe SE. Non-medical use of prescription analgesics: a three-year national longitudinal study. J Addict Dis 2009;28(3):232-242.
14. Sung HE, Richter L, Vaughan R, Johnson PB, Thom B. Nonmedical use of prescription opioids among teenagers in the United States: trends and correlates. J Adolesc Health 2005;37(1):44-51.
15. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008;300(22):2613-2620.
16. Ives TJ, Chelminski PR, Hammett-Stabler CA, Malone RM, Perhac JS, Potisek NM, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006;6:46.
17. British Pain Society. Recommendations for the appropriate use of opioids for persistent non-cancer pain. London (UK): The Society; 2004.
18. Jovey RD, Ennis J, Gardner-Nix J, Goldman B, Hays H, Lynch M, et al. Use of opioid analgesics for the treatment of chronic noncancer pain a consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manag 2003;8 Suppl A:3-28.
19. Bacovsky R, Maclure M, Nguyen A, Lopatka H, Regier L, Bugden S, et al. Canadian Academic Detailing Collaboration: evaluating processes and outcomes of academic detailing. Can Pharm J 2006;54-7.
20. Washington State. Washington State Agency Medical Directors' Group. Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain: an educational pilot to improve care and safety with opioid treatment. 2007. Olympia (WA): The Group.
21. National Opioid Use Guideline Group. Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. Hamilton (ON): McMaster University National Pain Centre; 2010. Available from: http://nationalpaincentre.mcmaster.ca/opioid/
22. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009;181(12):891-896.
23. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003;10(2):67-71.
24. Institute for Clinical Evaluative Sciences. Improving health care data in Ontario. ICES Investigative Report. Toronto: Institute for Clinical Evaluative Sciences; 2005.
25. Hall S, Schulze K, Groome P, Mackillop W, Holowaty E. Using cancer registry data for survival studies: the example of the Ontario Cancer Registry. J Clin Epidemiol 2006;59(1):67-76.
26. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163(4)481-486.
27. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009;339:b2942.
28. Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 2009;120(23):2310-2312.
29. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage 2001;22(2)672-687.
30. Canadian Pharmaceutical Association. Compendium of pharmaceuticals and specialties. Ottawa: The Association; 2008.
31. Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med 1997;16(7)791-801.
32. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152(2)85-92.
33. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006;31(6):506-511.
34. Overdose deaths involving prescription opioids among Medicaid enrollees Washington, 2004-2007. MMWR Morb Mortal Wkly Rep 2009;58(42)1171-1175.
35. Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am J Med 2006;119(4)292-296.
36. Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage 1999;18(1)27-37.
37. Anderson GM, Lexchin J. Strategies for improving prescribing practice. CMAJ 1996;154(7):1013-1017.